Immunotherapy

Article	Citations
Combining in Situ Vaccination and Immunogenic Apoptosis to Treat Cancer	68
Volume Increase of Spleen in Melanoma Patients Undergoing Immune Checkpoint Blockade	57
Immunotherapeutic Approach for Advanced Pancreatic Adenocarcinoma	55
Association Between PD-L1 Inhibitor, Tumor Site and Adverse Events of Potential Immune Etiology Within the US FDA Adverse Event Reporting System	45
Serplulimab monotherapy in extensive-stage small-cell lung cancer with brain metastasis: a case report	35
Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, Myasthenia Gravis and Transaminitis: A Case Series and Review	35
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors	33
Immunotherapy in Neoadjuvant Setting in Muscle-Invasive Bladder Cancer, What’s New?	32
Tackling the Immunotherapy Conundrum: Advances and Challenges for Operable Non-Small-Cell Lung Cancer Treatment	31
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma	31
Neoadjuvant Immunotherapy Plus Chemotherapy and Adjuvant Targeted Therapy in ALK -Positive Non-Small-Cell Lung Cancer	27
Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center	27
Gene Signatures with Therapeutic Value: Emerging Perspective for Personalized Immunotherapy in Renal Cancer	27
Boosting the Abscopal Effect with Chemoradiotherapy/Immunotherapy Combination in Metastatic Cervical Cancer: A Case Report	27
Efficacy and Safety of Pembrolizumab Combined with Albumin-Bound Paclitaxel and Nedaplatin for Advanced Esophageal Squamous Cell Carcinoma	26
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review	25
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events	22
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma	22
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease	21
Immune Checkpoint Inhibitors in Follicular Dendritic Cell Sarcoma	19
Peripheral B-cell Levels Predict Efficacy and Overall Survival in Advanced Melanoma Patients Under PD-1 Immunotherapy	18
CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology	17
Effect of Sublingual Immunotherapy on Clinical and Laboratory Autoimmunity	17
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis	17
Cost–Effectiveness Analysis of Nivolumab Plus Cabozantinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma	16

Tocilizumab in Grade 4 Hepatitis Secondary to Immune Checkpoint Inhibitor: A Case Report and Review of the Literature	15
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy	15
B Cells and Their Rolexs in Shaping the Immune Response in Squamous Cell Carcinoma of the Head and Neck	15
What Role will Ensifentrine Play in the Future Treatment of Chronic Obstructive Pulmonary Disease Patients? Implications from Recent Clinical Trials	15
Enteric Plexus Neuropathy Associated with PD-L1 Blockade in a Patient with Small-Cell Lung Cancer	14
Immunotherapy Versus Standard Chemotherapy For Treatment of Extensive-Stage Small-Cell Lung Cancer: A Systematic Review	14
Pembrolizumab-Associated Erythema Nodosum in the Treatment of Metastatic Melanoma	13
Gastrointestinal Treatment-Related Adverse Events of Combined Immune Checkpoint Inhibitors: A Meta-Analysis	13
Toripalimab and Anlotinib as a Maintenance Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report	13
The Dilemma of Neoadjuvant and Adjuvant Therapy in Urothelial Carcinoma: will Immunotherapy Solve the Problem?	13
Development of Hepatitis Triggered by SARS-CoV-2 Vaccination in Patient with Cancer During Immunotherapy: A Case Report	13
Takotsubo Syndrome in a Patient with Metastatic Renal Cell Carcinoma Treated with Pembrolizumab Plus Axitinib	12
Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database	12
Immune Cells and Signatures Characterize Tumor Microenvironment and Predict Outcome in Ovarian and Endometrial Cancers	12
Safe Anti-Programmed Cell Death-1 Rechallenge With Antibody Switching After Immune-Related Adverse Events: Brief Communication	12
Clinical Course and Management of Pembrolizumab-Associated Isolated Adrenocorticotrophic Hormone Deficiency: A New Case and Literature Review	11
Health and Economic Impact of Subcutaneous Allergen Immunotherapy in Patients with Pollen-Induced Allergic Rhinoconjunctivitis: Real-Word Evidence from the Czech Republic	10
Lichenoid Dermatitis Following Pd-1 Inhibitor-Induced Toxic Epidermal Necrolysis: A Case Report and Literature Review	10
Fatal Toxicity Induced by anti-PD-1 Immune Checkpoint Inhibitor in Thymic Epithelial Tumor	10
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy	9
Lights and Shadows on the Role of Rhg-CSF in Cancer Patients During the COVID-19 Pandemic and Future Perspectives of Research	9
Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation	9
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes	9
Severe Pseudomembranous Keratoconjunctivitis with Deterioration of Eyesight Induced by Immune Checkpoint Inhibitors	9
Nimotuzumab for COVID-19: Case Series	9
A Case Report of Pulmonary Nocardiosis During Pembrolizumab: The Emerging Challenge of the Infections on Immunotherapy	9
Keeping it Real: Implications of Real-World Treatment Outcomes for First-Line Immunotherapy in Metastatic Non-Small-Cell Lung Cancer	9
Combined Response of Advanced Cutaneous Squamous Cell Carcinoma and Renal Cell Carcinoma to Immunotherapy: A Case Report	9
Herpes Zoster in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors	8
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia	8
Immune Checkpoint Inhibitors for Advanced or Metastatic Basal Cell Carcinoma: How much Evidence do we Need?	8
Metastatic Gastric Cancer: Synergizing and Sequencing Targeted Therapy with First-Line Immunotherapy	8
Production of Hyperimmune Anti-SARS-CoV-2 Intravenous Immunoglobulin from Pooled COVID-19 Convalescent Plasma	8
Tezepelumab for the Treatment of Severe Asthma: A Plain Language Summary of the PATHWAY and NAVIGATOR Studies	8
Development of A Novel Shared Decision Making Aid for Primary Immunodeficiency Diseases	8
Association Between Sex and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta Analysis	8
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So €˜Pure’	8
Successful Treatment with Carboplatin and Paclitaxel in Melanoma Progression After Immune-Related Adverse Events	8
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar	8
Real-world Maintenance Therapy and Survival Outcomes For Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA	8
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study	7
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database	7
Deterioration in multifocal motor neuropathy upon treatment of immune-related adverse events of checkpoint inhibition	7
Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait	7
Satisfaction, Qol and adherence of patients allergic to dust mites and/or pollens undergoing sublingual immunotherapy	7
Durable Response After Immune Checkpoint Inhibitor-Related Diabetes in Mismatch Repair-Deficient Pancreatic Cancer	7
Are Immune Checkpoint Inhibitors Safe and Effective in Lung Cancer Patients with Pre-Existing Interstitial Lung Disease?	7
Management of Immune-Mediated Toxicities and their Implications in the Outcomes of Advanced Kidney Cancer	7
Case reports of immune-related cystitis and the antibody combination hypothesis	6
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy	6

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab	6
The Future of Immunotherapy in Advanced Renal Cell Carcinoma: Beyond PD-1/PD-L1 Inhibitors	6
A Case of Pembrolizumab-Induced Fulminant Type 1 Diabetes Mellitus in Breast Cancer	6
Postvaccination immune-mediated hepatitis: what do we really know?	6
Chimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward	6
Update on Immunotherapy in the Management of Gallbladder Cancer	6
Immune-Checkpoint Inhibitors Versus Other Systemic Therapies in Advanced Head and Neck Cancer: a Network Meta-Analysis	6
Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment	6
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study	6
Anti-PD-1 Treatment-Induced Immediate Central Diabetes Insipidus: A Case Report	6
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)	6
Immunotherapy for Gastric Cancer: A 2021 Update	6
Anti-PD-1 and Regorafenib Induce Severe Multisystem Adverse Events in Microsatellite Stability Metastatic Colorectal Cancer: A Case Report	6
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma	6
Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature	6
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?	6
Pembrolizumab in an HIV-infected patient with glioblastoma	6
Systemic Immune–Inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis	6
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China	6
Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis	6
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis	6
The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis	6
Use of Upadacitinib in the Treatment of Psoriatic Arthritis	6
Toxic Epidermal Necrolysis Associated with Chemoimmunotherapy For Lymphoma: Case Report and Literature Review	6
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer	5
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas	5
Mechanisms of Allergen Immunotherapy Supporting its Disease-Modifying Effect	5
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)	5
Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report	5
Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review	5
Pretreatment Lung Immune Prognostic Index as a Biomarker in Advanced Non-Small-Cell Lung Cancer Patients Receiving First Line Pembrolizumab	5
Durable Response after Immunotherapy Discontinuation for Delayed and Severe Immune-related Adverse Event: A Case Report	5
The Safety and Efficacy of Immune-Checkpoint Inhibitors in Patients with Cancer and Pre-Existing Autoimmune Diseases	5
Phase I Studies of Peptide Vaccine Cocktails Derived from GPC3, WDRPUH and NEIL3 for Advanced Hepatocellular Carcinoma	5
Capillary-Leak Syndrome: An Unrecognized Early Immune Adverse Effect of Checkpoint-Inhibitors Treatment	5
Advancing Immunotherapy in Gastroesophageal Cancer Through Rational Combinations and Biomarkers	5
Could senescent cells be the prescription for therapeutic cancer vaccines?	5
Distinct Sulfated Glycans Expressed in Intrahepatic Cholangiocarcinoma: A Potential Target for New Therapy	5
Fatal Cytokine-Release Syndrome in A Patient Receiving Toripalimab: A Case Report	5
Safe Use of Intravesical Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer During Breastfeeding: A Case Report	5
Col10A1 is a Potential Immunotherapy Biomarker Associated With Immune Infiltration and Deficient Mismatch Repair in Colon Cancer	5
Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis	5
A Novel Dose-Adjustment Protocol for Interrupted Subcutaneous Immunotherapy for Allergic Rhinitis	5
Unraveling the Nexus: Oncogenic Drivers and Immunotherapy Efficacy in Cancer Treatment	5
Comparative Effectiveness of First-Line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors According to IMDC Risk Groups in Metastatic Renal Cell Carcinoma: A Meta-Analysis	5
Enhanced Binding at Fever Temperatures of HER2 in Complex with Trastuzumab and Pertuzumab	5
Prolonged Clinical Remission of Type 1 Diabetes Sustained by Calcifediol and Low-Dose Basal Insulin: A Case Report	5
Secukinumab in the Treatment of Hidradenitis Suppurativa	5
Comparing Bacillus Calmette-GuéRin (Bcg) Strains in Convalescent Covid-19 Patients	5
Selection of allergen extract for immunotherapy in polysensitized allergic rhinitis patients	5
Coexpression of C-Jun in Multiple-Chain DAP-CAR-engineered T-Cells for Solid Tumor Therapy	5
Colitis Presenting 5 Months after the Final Dose of Anti-Pd-1: Long-Term Monitoring is Warranted after Adjuvant Therapy	5
Safety of Subcutaneous and Sublingual Immunotherapy with Allergoids in Children: A Real-Life Pharmacovigilance Study	5
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas	5
Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic	5
Pembrolizumab-Induced Follicular Eruption and Response to Isotretinoin	4
Association Between Age and Efficacy of First-Line Immunotherapy-Based Combination Therapies for Mrcc: A Meta-Analysis	4
Epicutaneous Immunotherapy with Viaskin Peanut in toddlers: a plain language summary	4
Safety and Effectiveness of Intravenous Ct-P13 in Inflammatory Arthritis: Post-Marketing Surveillance Study in Thailand	4
Immunotherapy in Hematological Malignancies: Recent Advances and Open Questions	4
Adherence to Subcutaneous Biological Therapies in Patients with Inflammatory Rheumatic Diseases and Inflammatory Bowel Disease: A Systematic Review	4
Immunology of Osteoporosis: Relevance of Inflammatory Targets for the Development of Novel Interventions	4
Adjuvant ArtinM favored the host immunity against Cryptococcus gattii infection in C57BL/6 mice	4
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158	4
Welcome to The 14th Volume of Immunotherapy	4
Mesenchymal Stem Cells Derived from Human Dental Follicle Modulate the Aberrant Immune Response in Atopic Dermatitis	4
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review	4
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study	4
Welcome to Immunotherapy Volume 16!	4
Immunoregulatory Effects of Dental Mesenchymal Stem Cells on T and B Lymphocyte Responses in Primary Sjögren's Syndrome	4
Antimicrobial/Anticancer Peptides: Bioactive Molecules and Therapeutic Agents	4
The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease	4
Hematological Prognosticators in Metastatic Renal Cell Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis	4
Immunotherapy with γδ T-cells: the future is there	4
Successful treatment of trichilemmal carcinoma with distant metastasis using pembrolizumab: a case report and review	4
Real-World Study of PD-L1 Testing Patterns and Treatment Distribution in Patients with Metastatic Non-Small-Cell Lung Cancer in Israel	4
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression	4
Toripalimab and Fruquintinib Therapy for Colorectal Cancer after Failed Multiline Chemotherapies: A Case Report	4
Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy	4
A Review of Phase Iii Clinical Trials of Us Fda-Approved Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyposis	4

Cutaneous Metastases at the Sites of Pembrolizumab-Induced Bullous Pemphigoid Lesions in a Patient with Melanoma	4
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data	4
The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus	4
Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey	4
Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics	4
Harnessing Gene Fusion-Derived Neoantigens for ‘Cold’ Breast and Prostate Tumor Immunotherapy	4
Urothelial Carcinoma in The Era of Immune Checkpoint Inhibitors	4